KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Work In Process (2016 - 2025)

Historic Work In Process for Halozyme Therapeutics (HALO) over the last 16 years, with Q4 2025 value amounting to $30.9 million.

  • Halozyme Therapeutics' Work In Process rose 248.93% to $30.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $30.9 million, marking a year-over-year increase of 248.93%. This contributed to the annual value of $30.9 million for FY2025, which is 248.93% up from last year.
  • As of Q4 2025, Halozyme Therapeutics' Work In Process stood at $30.9 million, which was up 248.93% from $34.8 million recorded in Q3 2025.
  • In the past 5 years, Halozyme Therapeutics' Work In Process ranged from a high of $56.2 million in Q3 2022 and a low of $6.3 million during Q1 2022
  • Its 5-year average for Work In Process is $31.9 million, with a median of $32.5 million in 2023.
  • Per our database at Business Quant, Halozyme Therapeutics' Work In Process tumbled by 6742.97% in 2022 and then surged by 33275.43% in 2023.
  • Halozyme Therapeutics' Work In Process (Quarter) stood at $17.5 million in 2021, then skyrocketed by 152.72% to $44.1 million in 2022, then dropped by 22.85% to $34.0 million in 2023, then decreased by 11.33% to $30.2 million in 2024, then rose by 2.49% to $30.9 million in 2025.
  • Its last three reported values are $30.9 million in Q4 2025, $34.8 million for Q3 2025, and $30.9 million during Q2 2025.